National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Axicabtagene Ciloleucel (Yescarta®)

Axi-cel is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy.

NCPE Assessment Process Complete
Rapid review received 10/09/2018
Rapid review completed 18/10/2018
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of axi-cel compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 22/10/2018
Pre-submission consultation with Applicant 03/12/2018
Submission received from Applicant 20/03/2019
Preliminary review sent to Applicant 15/10/2019
NCPE assessment re-commenced 13/11/2019
Preliminary review # 2 sent to Applicant 13/12/2019
NCPE assessment re-commenced 20/12/2019
Factual accuracy sent to Applicant 04/02/2020
NCPE assessment re-commenced 11/02/2020
NCPE assessment complete 21/02/2020
NCPE assessment outcome The NCPE recommend that axicabtagene ciloleucel (Yescarta®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments.*

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.